King Pharmaceuticals, Inc. (Nasdaq:KG)(Was KING) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : King Pharmaceuticals, Inc. (Nasdaq:KG)(Was KING)

KG 23.52

-4.6%

Oct 29 3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Harold Engstrom who wrote (21)	5/27/1999 6:46:00 PM
From: Quahog	Read Replies (1) of 61

A friend of mine, who works for King, describes the upside as this: King, and Monarch, are constantly looking for established products (drugs) that are profitable but not superstars, to purchase. King then remarkets the product in the hope of boosting sales. The upside then, according to this fellow, is that there is very little risk and a lot of potential. King may not become a superstar overnight, but it should continue a slow and steady rise in that direction. Plus, for a pharmaceutical company, the price is right. Whether this is simply the company line, or the truth, I do not know. It sounds reasonable to me. Quahog

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next